Nicholas C. Nicolaides

Nicholas C. Nicolaides, Ph.D. is the President, Chief Executive Officer and co-founder of Navrogen™ Inc., a biopharmaceutical company developing targeted therapies for the treatment of cancer and immune-related disorders. From 2000 to 2018 he was the President, Chief Executive Officer and co-founder of Morphotek® Inc., […]

read more

Luigi Grasso

Luigi Grasso, Ph.D. is the Sr Vice President, Chief Scientific Officer and co-founder of Navrogen Inc. Prior to co-founding Navrogen, he was Vice President, CSO and co-founder of Morphotek Inc., a private biopharmaceutical company specializing in the development of antibody-based therapies for cancer, which […]

read more

Steven Kyriakos

Steven Kyriakos is the Vice President of Finance and Operations of Navrogen Inc. Prior to Navrogen, he was the Executive Director of Accounting and Finance at Morphotek Inc., a private biopharmaceutical company specializing in the development of antibody-based therapies for cancer, which was acquired […]

read more

Brad Kline

Brad Kline, Ph.D. is the Senior Director of Research and Development at Navrogen Inc.  Prior to joining the Navrogen team, he was responsible for overseeing antibody discovery and development at Morphotek Inc. During his tenure at Morphotek, he oversaw the engineering and […]

read more

Navrogen’s Mission

To be an industry leader in the area of humoral immuno oncology (HIO), a process whereby tumors produce factors that suppress the beneficial effects of patient’s immune systems against cancer as well as the therapeutic effects of antibody-based anti-cancer therapies. We are […]

read more